OLMA
NASDAQ · Biotechnology
Olema Pharmaceuticals Inc
$9.82
-0.08 (-0.81%)
Open$9.88
Previous Close$9.90
Day High$9.93
Day Low$9.75
52W High$36.26
52W Low$6.65
Volume—
Avg Volume1.09M
Market Cap864.48M
P/E Ratio—
EPS$-2.12
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+71.2% upside
Current
$9.82
$9.82
Target
$16.81
$16.81
$15.48
$16.81 avg
$21.94
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 273.28M | 252.57M | 215.43M |
| Net Income | -27,842,007 | -24,319,116 | -27,608,347 |
| Profit Margin | -10.2% | -9.6% | -12.8% |
| EBITDA | -48,708,771 | -44,721,101 | -36,525,999 |
| Free Cash Flow | -19,743,741 | -20,820,819 | -13,833,937 |
| Rev Growth | +22.4% | +21.1% | -4.4% |
| Debt/Equity | 0.25 | 0.24 | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $265.21 | +0.28% | 74.0 | 466.74B |
| AMGN | Amgen Inc | $410.24 | +4.34% | 23.7 | 207.25B |
| GILD | Gilead Sciences Inc | $152.67 | +1.40% | — | 187.10B |
| VRTX | Vertex Pharmaceuticals Inc | $514.99 | +0.84% | 29.7 | 130.64B |
| REGN | Regeneron Pharmaceuticals | $803.90 | +0.72% | 18.6 | 80.58B |
| ALNY | Alnylam Pharmaceuticals Inc | $251.65 | +3.00% | 40.0 | 32.33B |